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PAbstract
There are indications that inhibitors of the cyclooxygenase-2 (COX-2) enzyme may cause inhibition of angiogenesis, proliferation of
endothelial cells and induce apoptosis in cell systems. The concentrations of inhibitors required for such effects are however much higher than
those needed to inhibit COX-2, suggesting that the latter may not be involved in these actions of the drugs. We have however generated data that
strongly indicates a critical role for COX-2 suppression in the inhibition of angiogenesis and induction of apoptosis in human cultured umbilical
vein endothelial cells (HUVECs) by the selective cyclooxygenase-2 (COX-2) inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene
(DuP-697). DuP-697 concentration-dependently inhibited prostaglandin E2 (PGE2) production by HUVECs and at its known IC50 for COX-2
inhibition of 10 nM inhibited basal and vascular endothelial cell growth factor (VEGF)-induced PGE2 production by 80% and 85% respectively.
DuP-697 also induced apoptosis as shown by FACs analysis, an increase in chromatin condensation and DNA laddering in HUVECS treated with
the drug. Moreover, these effects were reversed by PGE2 and by VEGF. In parallel studies, DuP-697 induced caspases 3, 8 and 9, with the
caspase-3 specific inhibitor N–Acetyl–Asp–Glu–Val–Asp–al (DEVD–CHO) blocking the induction of apoptosis. Capillary-like tubule formation
by HUVECs cultured on Matrigel was inhibited by DuP-697 and this inhibition was prevented by PGE2 but not by DEVD–CHO. These results
indicate that the induction of apoptosis and inhibition of tubule formation by DuP-697 involves the inhibition of COX-2 and that whereas the
induction of apoptosis is caspase-dependent, the inhibition of tubule formation occurs through a caspase-independent mechanism.
© 2007 Published by Elsevier B.V. RRKeywords: Angiogenesis; Apoptosis; Human umbilical vein endothelial cell; DuP-697; Cyclo-oxygenase-235
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CO1. Introduction
Cyclooxygenase (COX) enzymes convert arachidonic acid to
prostaglandin H2 (PGH2) and exist as two distinct isoforms
referred to as COX-1 and COX-2. The COX-1 enzyme is mainly
constitutively expressed, but it can be induced by some growth
factors such as vascular endothelial growth factor (VEGF)
(Akarasereenont et al., 2002; Murphy and Fitzgerald, 2001).
COX-1 is the predominant isoform in most tissues including the
vascular endothelium, renal system and gastric mucosa and in45
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A2 (Parente and Perretti, 2003; Vane et al., 1998). By
comparison, COX-2 is only constitutively expressed in a few
tissues including the rat cecum (Kargman et al., 1996), brain
(Breder et al., 1995), renal system (Harris et al., 1994), but it is
inducible in a wide variety of cells (Vane et al., 1998) and in the
vasculature under conditions of shear stress (Inoue et al., 2002).
In contrast to the physiological role played by COX-1 in the
body, expression of COX-2 is associated mainly with the
induction of inflammation (Colville-Nash and Gilroy, 2000;
Masferrer et al., 1995; Parente and Perretti, 2003; Seibert and
Masferrer, 1994; Vane et al., 1998) or angiogenesis (Carmeliet,
2000; Masferrer et al., 2000). Prostaglandins catalysed by
COX-2 also control vasodilatation and blood pressure in areas of
inflammation causing an increase in swelling, an influx ofmation and induction of apoptosis in human endothelial cells by the selective
e (DuP-697). Eur. J. Pharmacol. (2007), doi:10.1016/j.ejphar.2007.06.057
C50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
2 A. Churchman et al. / European Journal of Pharmacology xx (2007) xxx–xxx
ARTICLE IN PRESSUN
CO
RR
E
immune cells, and an increase in pain in the area (Masferrer et al.,
1995; Seibert and Masferrer, 1994). However, in the gastric
mucosa, COX-2 may catalyse the formation of cytoprotective
prostaglandins such as prostacyclin and prostaglandin E2 that
could maintain gastric blood flow and mucosal integrity
(Takeeda et al., 2004).
The increase in swelling and vasodilatation associated with
inflammation can be prevented by inhibiting the COX-2 enzyme
pharmacologically. The first generation of compounds found to
inhibit COX-2 were the non-steroidal anti-inflammatory drugs
(NSAIDs). These compounds are, however, non-selective and
effectively inhibit both COX-1 and COX-2 (Mitchell et al.,
1993). As a consequence of this, chronic treatment with NSAIDs
may result in severe undesirable side effects such as gastroin-
testinal toxicity and ulcer formation due to the inhibition of
COX-1 and/or COX-2 derived cytoprotective prostaglandins
(Allison et al., 1992; Mitchell et al., 1993). Indomethacin, a first
generation NSAID, inhibits both COX-1 and COX-2, but it is
selective for the inhibition of COX-1 at low concentrations and
only inhibits COX-2 at ≥3 μM (Mitchell et al., 1993).
Indomethacin has also been shown to induce apoptosis in in
vivo gastric cancer models (Sawaoka et al., 1998) and in vitro in
HT-29 cells (Hong et al., 1998).
Recently, a new generation of selective COX-2 inhibitors
have been introduced and include 5-bromo-2-(4-fluorophenyl)-
3-(methylsulfonyl) thiophene (DuP-697) (Gierse et al., 1995).
This new class of inhibitors binds tightly to the COX-2 active
site and dissociate slowly, thus having a longer lasting action.
Moreover, their selectivity for COX-2 means that the activity of
COX-1 remains unaffected, thereby preventing gastrointestinal
injury and ulcer formation (Schmassmann et al., 1998).
Expression of COX-2 can be induced by various growth
factors such as VEGF (Akarasereenont et al., 2002; Hernandez
et al., 2001; Wu et al., 2006) which may act through the p38
MAP kinase and Jun kinase (JNK) signalling pathways (Wu
et al., 2006) and subsequently activate transcriptional regulators
on the COX-2 promoter including the nuclear factor of activated
T-cells (NFAT) (Hernandez et al., 2001; Liu et al., 2003). The
increase in COX-2 protein expression may enhance the
production of prostaglandin E2 (PGE2), resulting in either an
autocrine or paracrine action that enhances expression of VEGF
through the early regulating kinase (ERK) 2 and/or the
generation of hypoxia induced factor (HIF)-1α (Calviello
et al., 2004; Huang et al., 2005).
Since VEGF is critical for angiogenesis (Breier et al., 1992),
its regulation by COX-2 suggests that this enzyme may act as an
important mediator in this process. Indeed, selective inhibition of
COX-2 activity has been shown to inhibit angiogenesis dose
dependently and this was associated with a decrease in growth
factor (VEGF and bFGF) expression, inhibition of proliferation
of endothelial cells both in vitro and in vivo and induction of
apoptosis (Hernandez et al., 2001; Leahy et al., 2002; Sawaoka
et al., 1999; Yazawa et al., 2005). However the concentrations of
drugs required for these effects were much higher than those
required to inhibit COX-2, suggesting perhaps that the effects of
the inhibitors on angiogenesis may be independent of their
ability to inhibit COX-2 and that the two processes may not bePlease cite this article as: Churchman, A. et al. Inhibition of angiogenic tubule for
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1linked. To address this issue, we have examined the effects of
1DuP-697 on capillary like tubule formation of human umbilical
1vein endothelial cells (HUVECs) at concentrations that
1selectively inhibit COX-2 and compared the effects with those
1of indomethacin used at concentrations that selectively inhibit
1COX-1. We report that DuP697 inhibits angiogenesis via
1specific inhibition of COX-2 and augments the induction of
1apoptosis at concentrations that are pharmacologically relevant.
12. Materials and methods
12.1. Materials
1All chemicals and cell culture medium was supplied by
1Sigma (UK) unless stated. ELISAs for PGE2 and 6-keto-PGF2α
1were supplied by R & D systems (Europe). DuP-697 was
1supplied by Tocris-Cookson. Anti-COX-2 primary antibody and
1the anti-goat HRP conjugate antibody were supplied by Insight
1Biotechnology Ltd (UK). The anti-caspase 3, 8 and 9 antibodies,
1VEGF and PGE2 were supplied by Merck Biosciences (UK).
1DuP-697 was from Tocris-Cookson, UK. β-actin antibody was
1from Merck Biosciences, UK. BCA kit was from Pierce Ltd,
1UK.
12.2. Cell culture
1Human umbilical vein endothelial cells (HUVECs) were
1isolated according to standard procedures (Hallam et al., 1988)
1and cultured in gelatin-coated T25 flasks in Medium 199
1supplemented with 20% heat-inactivated foetal calf se-
1rum, penicillin (100 units/ml), streptomycin (0.1 mg/ml) and
1L-glutamine (2 mM). Cells were maintained at 37 °C in 5% CO2
1humidified tissue culture incubator. Cell were routinely passaged
1when 80 to 90% confluent and were used between passages 1
1and 4.
12.3. VEGF165 treatment of quiesced HUVECs
1Confluent monolayers of HUVECs were quiesced for 16 h in
1serum free Medium 199 (SFM). VEGF165 (50 ng/ml) was then
1added and cells were further incubated for up to 24 h.
12.4. Cell treatments
1Cell monolayers (passage 1–4) were treated with DuP-697 or
1indomethacin for up to 24 h at the concentrations indicated. In
1parallel experiments, cells were incubated for 24 h with DuP-697
1simultaneously with prostaglandin E2 (PGE2; 10 μM), VEGF165
1(50 ng/ml) or N–Acetyl–Asp–Glu–Val–Asp–al (DEVD–CHO;
110 μM).
12.5. Staining for condensed chromatin
1HUVECs were plated at 3×105 cells/ml in gelatinised 24
1well plates and cultured in 20% foetal bovine serum (FBS),
12 mM L-glutamine and 100 units/ml penicillin, 0.1 mg/ml
1streptomycin supplemented Medium 199 (complete mediummation and induction of apoptosis in human endothelial cells by the selective
e (DuP-697). Eur. J. Pharmacol. (2007), doi:10.1016/j.ejphar.2007.06.057
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Fig. 1. Cyclooxygenase-2 expression in HUVECs. HUVECs were quiesced for
16 h in 1% FCS Medium 199 and then exposed to VEGF for 0–24 h. COX-2
expression in HUVECs cultured in Medium 199 containing 20% FCS for 24 h is
also shown (S). Positive control for the antibody was assessed using J774
murine macrophages treated with lipopolysaccharide for 24 h (+ve). The image
is representative of 3 separate experiments.
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199). The cells were treated with DuP-697 (10 nM) or
indomethacin (3 μM) diluted in serum free medium (SFM). In
corresponding experiments PGE2 (10 μM) or VEGF165 (50 ng/
ml) was added simultaneously with DuP-697 (10 nM). After
24 h, the cells in the supernatant were counted and resuspended
in sterile phosphate buffered saline (PBS) at 1x104 cells/ml. The
cells were cytospun onto glass slides at 750 rpm for 10 min and
fixed with 3.7% formaldehyde. The slides were washed, allowed
to dry at room temperature before staining with acridine orange
(5 μM) for 5 min. Excess stain was washed off and the slides
again dried before placing a coverslip over the cells for
visualisation at 405 nm under a fluorescent microscope. Cells
showing condensed chromatin were counted as positive for
apoptosis.
2.6. Flow cytometry analysis of apoptosis
HUVECs (3×105/ml) were plated in gelatinised 6 well plates
and treated with DuP-697 as above. After 6 h, the cells in the
supernatant were removed and stored. The adherent cells were
removed from the monolayer using Accutase ® solution (Sigma)
for 1 min at 37 °C. The adherent cells were pooled with the cells
in the supernatant and centrifuged at 1000 rpm for 5 min. The
cell pellet was resuspended in binding buffer (supplied as part of
the annexin-V FITC apoptosis detection kit (Sigma)) at
1×106 cells/ml. To the cell suspension 5 μl of annexin-V
FITC and 10 μl propidium iodide was added and incubated for
10 min at room temperature. Fluorescence of the cells was
determined using the Coulter flow cytometer.
2.7. Apoptotic DNA laddering
HUVECs (1×105/ml) were plated in gelatinised 24 well
plates and treated as above. Cells in the supernatant were
centrifuged and lysed in 10 mM EDTA, 50 mM Tris-HCl, 0.5%
SDS, and 0.5 mg/ml proteinase K on ice for 30 min. Cell lysate
was treated with RNase A (1 μg/ml) and DNA was extracted
using phenol/chloroform. DNA samples were run on 2% agarose
gels at 80 V until the dye front was 3 cm from the bottom of the
gel. Gels were visualised by staining in ethidium bromide (1 μg/
ml) for 20 min and exposure to ultraviolet light.
2.8. Quantification of prostaglandins by ELISA
HUVECs were plated and treated as above and the
supernatant removed for analysis. PGE2 and 6-keto-PGF2α
were quantified by ELISA according to the manufacturer's
instructions.
2.9. Tubule formation
Matrigel ECM (40 μl) was added to pre-cooled (−20 °C)
sterile 96 well plates and allowed to set at 37 °C for 30 min.
HUVECs (100 μl diluted to 2×105 cells/ml in supplemented
Medium 199) were added to each well together with DuP-697
(10 nM) and VEGF165 (50 ng/ml) and PGE2 (10 μM) as
required. Cells were incubated at 37 °C. Tubule formation wasPlease cite this article as: Churchman, A. et al. Inhibition of angiogenic tubule for
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assessed 8 h later under light microscopy at ×400 magnification.
Tubule formation was positively identified when HUVECs had
migrated to make physical contact with each other to form a full
tubule (adapted from (Scappaticci et al., 2001; Smith and
Hoffman, 2005).
2.10. Western blotting
Total cell protein in lysates generated from experiments was
determined by the bicinchoninic acid (BCA) assay and western
blot analysis performed as described previously (Smith and
Hoffman, 2005). Equal concentrations of protein were loaded for
each sample (20 μg for COX-2; 90 μg for caspase analysis).
COX-2 was identified using a specific polyclonal goat anti-
COX-2 primary antibody (0.2 μg/ml) and a horse-radish
peroxidase conjugated anti-goat secondary antibody (0.08 μg/
ml). Caspases were identified using mouse anti-caspase primary
antibody (0.15 μg/ml) selective for either caspase 3, 8 or 9. A
horse-radish peroxidase conjugated anti-goat IgG (0.08 μg/ml)
was used as the secondary antibody. Levels of β-actin were
analysed to confirm that equal concentrations of protein were
loaded. Bands were quantified by densitometry using a Gene
Genius Bioimaging system (Syngene).
2.11. Statistical analysis
Statistical significance of apoptosis, tubule formation and
PGE2 production was carried out using two-way ANOVA and
confirmed with an unpaired student's t-test. All graphical data
are the mean of at least three separate experiments with three
replicates for each data point; for which the standard error was
calculated.
3. Results
3.1. Expression of COX-2 in HUVECs
HUVECs grown in medium containing 20% serum expressed
low levels of COX-2 protein, as determined by western blot
(Fig. 1). When cells quiesced in SFM were subsequently
stimulated with VEGF there was a time-dependent increase in
COX-2 expression with maximal expression occurring by 8 h
and COX-2 expression was maintained for 24 h after the
addition of VEGF (Fig. 1).mation and induction of apoptosis in human endothelial cells by the selective
e (DuP-697). Eur. J. Pharmacol. (2007), doi:10.1016/j.ejphar.2007.06.057
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Fig. 2. Inhibition of prostaglandin E2 production by DuP-697 or indomethacin in
non-stimulated and VEGF stimulated HUVECs. Control cells were incubated
with 0.01% DMSO or 0.01% methanol for 24 h. PGE2 levels were determined
by ELISA. Values are mean±s.e.m. of 3 independent experiments each with 3
replicates. Statistical significance was determined using Student's t-test
compared to either the DMSO or methanol controls. ⁎denotes Pb0.05.
Fig. 4. Induction of chromatin condensation in HUVECs by DuP-697. HUVECs
cultured in serum free media were treated with DuP-697 (0.1–100nM) for 24 h
at 37 °C prior to cytospinning and staining of the DNA with acridine orange.
Control cells were incubated with DMSO (0.01%). Values are means±s.e.m. of
3 independent experiments with 2 replicates in each. Statistical significance was
determined using Student's t-test compared to the DMSO controls. ⁎denotes
Pb0.05.
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3.2. Inhibition of prostaglandin production by DuP-697and
Indomethacin
Under basal control conditions, PGE2 production by
HUVECs cultured in SFM for 24 h was 124 pg/ml. Incubation
with VEGF for 24 h increased PGE2 production to 262 pg/ml.
DuP-697 (0.01–10 μM) inhibited in a dose-dependent manner
both basal and VEGF-stimulated PGE2 production (Fig. 2).
DuP-697 at 10 nM (the IC50 for COX-2 inhibition) inhibited
basal and VEGF-stimulated PGE2 production by approximately
80% and 85% respectively and concentrations of DuP-697 of
1 μM and above inhibited both basal and VEGF-stimulated
PGE2 production byN90% (Fig. 2). Indomethacin (0.01–10 μM)
also inhibited basal and VEGF-stimulated PGE2 production
although higher concentrations were required for inhibition than
was seen for DuP-697 (Fig. 2).UN
CO
R 68
Fig. 3. Inhibition of 6-keto-prostaglandin F2α production by DuP-697 in non-
stimulated and VEGF stimulated HUVECs. Control cells were incubated with
0.01% DMSO for 24 h. PGF2α levels were determined by ELISA. Values are
mean±s.e.m. of 3 independent experiments each with 3 replicates. Statistical
significance was determined using Student's t-test compared to the DMSO
controls. ⁎denotes Pb0.05.
Please cite this article as: Churchman, A. et al. Inhibition of angiogenic tubule for
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D
P 2Levels of 6-keto- GF2α were measured as a marker of
2prostacyclin production. DuP-697 inhibited 6-keto-PGF2α
2production by ∼60% at concentrations of 0.01 μM and
20.1 μM in the non-stimulated cells. However, at the higher
2concentrations of DuP-697, 6-keto-PGF2α production appeared
2to return to basal levels. VEGF-stimulated cells exhibited a dose
2dependent inhibition of 6-keto-PGF2α with a maximal inhibition
2of 93% at 10 μM (Fig. 3).
23.3. Induction of apoptosis by DuP-697 and indomethacin
2DuP-697 at concentrations between 0.1 nM and 100 nM
2caused a dose-dependent increase in chromatin condensation of
2non-adherent HUVECs in SFM (Fig. 4). By contrast, indometh-
2acin only induced a statistically significant increase in chromatin
2condensation at 3 μM and above, concentrations that have been
2shown to inhibit COX-2 (Fig. 5). There was no chromatinFig. 5. Induction of chromatin condensation in HUVECs by indomethacin.
HUVECs cultured in serum free media were treated with indomethacin (0.01–
10μM) for 24 h at 37°C prior to cytospinning and staining of the DNA with
acridine orange. Control cells were incubated with methanol (0.01%). Values are
means±s.e.m. of 3 independent experiments with 2 replicates in each. Statistical
significance was determined using Student's t-test compared to the methanol
controls. ⁎denotes Pb0.05.
mation and induction of apoptosis in human endothelial cells by the selective
e (DuP-697). Eur. J. Pharmacol. (2007), doi:10.1016/j.ejphar.2007.06.057
TE
D
PR
OO
F
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
Fig. 6. Assessment of DuP-697-induced apoptosis in HUVECs by Flow
cytometry. HUVECs were treated with DuP-697 for 6 h at 37 °C prior to staining
with Annexin-V FITC and propidium iodide and analysed by flow cytometry.
Control cells were incubated with DMSO (0.01%). The data represents fold
change in annexin-V FITC labelled cells and is the means±s.e.m. of 3
independent experiments with 2 replicates in each. Statistical significance was
determined using Student's t-test compared to the DMSO controls. ⁎denotes
Pb0.05.
Fig. 8. Caspase expression in HUVECs. HUVECs cultured in serum free media
(SFM) were treated with DuP-697 (10 nM) for 0–8 h and then assayed for
(A) caspase-9, (B) caspase-8, (C) caspase-3. Control cells were incubated for 8 h
with DMSO (0.01%). Caspase expression was quantified by densitometry (D). The
images are representative of 3 experiments. Values represent mean±s.e.m. of 3
experiments. Statistical significance was determined using Student's t-test
compared to the DMSO controls. ⁎denotes Pb0.05.
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condensation in adherent cells under any of these conditions
(data not shown). Parallel studies conducted with flow cytometry
(FACs) to confirm the pro-apoptotic actions of DuP-697 showed
a concentration-dependent increase in annexin-V FITC stained
cells which mirrored that in the acridine orange stained cells
described above. The maximum effect, as seen with acridine
orange staining, was produced by 10 nMDuP-697 which caused
a 2.5-fold increase in apoptotic cells and this was not further
enhanced with higher concentrations of the drug (Fig. 6). No
change in staining was observed in the propidium iodide only
stained cells or the cells stained by both annexin-V FITC and
propidium iodide (data not shown).
The benchmark DNA laddering analysis was also carried out to
evaluate apoptosis of HUVECs cultured in SFM. DuP-697UN
CO
R
Fig. 7. Induction of apoptotic DNA fragmentation in HUVECs. HUVECs were
treated with DuP-697 (10 nM) for 24 h at 37 °C prior to DNA extraction by
phenol/chloroform followed by 2% agarose gel electrophoresis and staining
with ethidium bromide. Control cells were incubated at 37 °C for 24 h with
DMSO (0.01%). Lanes: (1) DNA ladder; (2) DMSO (0.01%) control;
(3) Actinomycin-D positive control (200 nM); (4) DuP-697 (10 nM). The
image is representative of 3 separate experiments.
Please cite this article as: Churchman, A. et al. Inhibition of angiogenic tubule for
cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophen(10 nM) induced high molecular weight DNA fragmentation and
the classical lower molecular weight (720 bp down to 180 bp)
DNA laddering after 24 h, which is indicative of apoptosis (Fig. 7).Fig. 9. Reversal of DuP-697 induced chromatin condensation by PGE2, CHO-
DEVDorVEGF165 inHUVECs.HUVECs cultured in serum freemedia (SFM)were
treated with DuP-697 (10nM) alone or in the presence of PGE2 (10 μM), caspase 3
inhibitor (CHO-DEVD) (12.5 μM) or VEGF (50 ng/ml) and incubated at 37 °C for
24 h. Cells were cytospun and stained with acridine orange. Control cells were
incubated for 24 h in serum free medium containing DMSO (0.01%). Values
represent means±s.e.m. of 3 experiments with 2 replicates in each. Statistical
significance was determined using Student's t-test compared to the DMSO controls.
⁎denotes Pb0.05.
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Fig. 11. Effect of indomethacin on HUVEC tubule formation. HUVECs in
complete media were treated with indomethacin (0.01–100 μM) for 8 h. Control
cells were incubated for 8 h in complete media with DMSO (0.01%). Values
represent means±s.e.m. of 3 experiments with 2 replicates in each. Statistical
6 A. Churchman et al. / European Journal of Pharmacology xx (2007) xxx–xxx
ARTICLE IN PRESSTo further confirm the induction of apoptosis with DuP-697,
caspase activation was examined using antibodies specific to the
active caspases. There was induction of caspases-8 (Fig. 8A, D)
and -9 (Fig. 8B, D) within 1 h of DuP-697 treatment and this
induction peaked at 2 h, declining thereafter. By comparison,
caspase-3 was maximally induced by 2 h with levels slowly
declined thereafter (Fig. 8C, D).
Incubations of cells with PGE2 (10 μM), the specific caspase-
3 inhibitor DEVD–CHO (12.5 μM) or VEGF (50 ng/ml)
completely reversed apoptosis induced with DuP-697 (10 nM)
(Fig. 9). These compounds also inhibited DuP-697-induced
DNA laddering (data not shown).
3.4. Effects of DuP-697 and indomethacin on in vitro
angiogenesis
In vitro angiogenesis was assessed by quantifying capillary-
like tubule formation of unstimulated and VEGF stimulatedUN
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Fig. 10. Capillary-like tubule formation of HUVECs. HUVECs were incubated
on Matrigel and tubules were photographed after 8 h (A–C). (A) complete
media+DMSO (0.01%), (B) DuP-697 (10nM), (C) DuP-697+PGE2 (10μM).
Tubules were quantified and expressed as a % of tubule formation in control
non-stimulated cells (D). CHO–DEVD was used at a concentration of 12.5 μM.
Values are means±s.e.m. of 3 experiments with 2 replicates in each. Statistical
significance was determined using Student's t-test compared to the DMSO
controls. ⁎denotes Pb0.05.
significance was determined using Student's t-test compared to the DMSO
controls. ⁎denotes Pb0.05.
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3HUVECs cultured on Matrigel. Control HUVECs formed
3tubules on Matrigel after an 8 h incubation at 37 °C
3(Fig. 10A, D). DuP-697 (10 nM) significantly inhibited tubule
3formation of unstimulated HUVECs (Fig. 10B, D). PGE2
3(10 μM) reversed the inhibition of tubule formation caused by
3DuP-697 (Fig. 10C, D). Incubation with the casapse-3 inhibitor
3DEVD–CHO did not prevent the DuP-697-induced inhibition of
3tubule formation (Fig. 10D).
3Similar results were obtained when capillary-like tubule
3formation was assessed in VEGF-stimulated HUVECs. VEGF
3treatment caused a small but statistically significant increase of
3tubule formation relative to control levels (Fig. 10D). VEGF
3induced tubule formation was significantly reduced by DuP-697
3(10nM) and this inhibition was reversed with PGE2 (Fig. 10D).
3Indomethacin only inhibited tubule formation at concentrations
3of 3 μM and above (Fig. 11).
34. Discussion
3The present work shows unequivocally that DuP-697 induces
3apoptosis and inhibits capillary-like tubule formation in
3HUVECs. This was confirmed using several approaches
3including analysis of chromatin condensation, FACs analysis,
3the distinctive DNA laddering and changes in caspase activation.
3In all these studies, the peak effects were observed at a
3concentration of 10 nM DuP-697, which is the IC50 value for
3inhibition of COX-2 activity in vitro (Gierse et al., 1995).
3Results from various cell types indicate that inhibition of
3COX-2 is associated with the induction of apoptosis whereas the
3inhibition of COX-1 may not be involved. COX-2 over-
3expression in endothelial cells has been shown to promote cell
3survival (Leahy et al., 2002). In U397 cells, inhibition of COX-1
3did not induce apoptosis whereas inhibition of COX-2 was
3required to induce apoptosis in vitro (Johnson et al., 2001;
3Riendeau et al., 1997). In our studies we have found that whereas
3DuP-697 induced apoptosis at concentrations specific for themation and induction of apoptosis in human endothelial cells by the selective
e (DuP-697). Eur. J. Pharmacol. (2007), doi:10.1016/j.ejphar.2007.06.057
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inhibition of COX-2, the non-selective COX inhibitor indo-
methacin induced apoptosis only when used at concentrations
known to inhibit COX-2 (≥3 μM; (Mitchell et al., 1993)) and it
had no effect when used at lower concentrations that specifically
inhibit COX-1. This supports the notion that COX-2 rather than
COX-1 is associated with cell survival and protection against
apoptosis in HUVECs.
Our studies also revealed that PGE2 or VEGF prevented
DNA laddering and chromatin condensation induced in
HUVECs by 10 nM DuP-697. These findings indicate that
both PGE2 and VEGF may protect against DuP-697 induced
apoptosis in these cells. Similarly, exogenous PGE2 has also
been shown to prevent apoptosis in HCA-7 human colon
carcinoma cells induced by selective COX-2 inhibition (Sheng
et al., 1998).
The concentration of DuP-697 that induced chromatin
condensation (10 nM) was the concentration that also inhibits
both PGE2 and 6-keto-PGF2α production. This suggests that
inhibition of COX-2 is very important for the induction of
apoptosis. Further work is required in order to identify the
specific prostanoid(s) that when inhibited triggers apoptosis. In
addition, several isoforms of prostaglandin E synthase (PGE)
have been identified, including the cytosolic PGEs (Tanioka
et al., 2000), microsomal PGEs-1 (Jakobsson et al., 1999) and
mPGEs-2 (Tanikawa et al., 2002). Thus it will be of interest to
evaluate which isoform(s) is responsible for PGE2 production in
HUVECs.
Several studies have implicated caspases as mediators of
apoptosis induced by COX-2 inhibitors. For instance, Basu et al.
(2005) have reported that 48 h treatment of MDA-MB-231 and
MDA-MB-468 breast cancer cells with celecoxib resulted in
caspase 3 and 7 dependent apoptosis. In our studies, caspases 3,
8 and 9 were induced by DuP-697. Since caspase cleavage does
not always reflect activation we conducted additional studies
aimed at inhibiting the activity of caspase 3 which is the effector
caspase in apoptosis. These studies were carried out using the
selective caspase-3 inhibitor DEVD–CHO which inhibited
chromatin condensation and prevented DNA laddering, con-
firming that DuP-697-induced apoptosis in HUVECs is caspase-
3 dependent.
Treatment of HUVECs with DuP-697 (10 nM) prevented
capillary-like tubule formation in vitro whereas the non-specific
COX inhibitor indomethacin only inhibited angiogenesis at
concentrations known to inhibit COX-2 (≥3 μM). These data
suggest that COX-2 is essential for tubule formation and that this
process may require PGE2 production since inhibition of tubule
formation by DuP-697 was reversed by exogenous PGE2 in our
studies. This notion is consistent with a report by Leahy et al
demonstrating that PGE2 prevented the inhibition of in vivo rat
cornea angiogenesis induced by celecoxib (Leahy et al., 2002).
Not only are the VEGF and PGE2 signalling pathways inter-
related, but, in addition, down-stream effectors of these
pathways regulate both apoptosis and angiogenesis. VEGF
may enhance COX-2 expression forming a positive feedback
loop that regulates both VEGF production and COX-2 induction
(Caughey et al., 2001). VEGF binding and the production of
PGE2 have been shown to be important in αVβ3 integrinPlease cite this article as: Churchman, A. et al. Inhibition of angiogenic tubule for
cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophenTE
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binding and cell survival (Dormond et al., 2002; Leahy et al.,
2002; Yazawa et al., 2005). Inhibition of PGE2 decreased αVβ3
integrin expression and activated apoptosis through the
inhibition of Bcl-2 expression and subsequent caspase 9
activation or Fas receptor trimerisation and activation of caspase
8 (Aoudjit and Vuori, 2001; Dormond et al., 2002; Pollman
et al., 1999). In relation to angiogenesis, the products of COX-2,
including PGE2 and TXA2, play an important role in cellular
migration and tubule formation with specific inhibition of PGE2
and TXA2 preventing proliferation and angiogenesis (Jantke
et al., 2004; Wu et al., 2003). PGE2 may induce VEGF
expression through binding to the EP4 receptor and activating
the JNK and HIF-1α pathways (Ghosh et al., 2000; Huang et al.,
2005; Kuwano et al., 2004). PGE2 has also been shown to
increase binding of endothelial cells to the extracellular matrix
(ECM) through αVβ3 dependent mechanisms (Leahy et al.,
2002; Yazawa et al., 2005).
In summary, the selective COX-2 inhibitor DuP-697 has been
found to induce apoptosis and prevent capillary-like tubule
formation in vitro at pharmacologically relevant concentrations.
The effects observed may possibly be due to the specific
inhibition of COX-2 by DuP-697 with a subsequent decrease in
PGE2 production. Moreover, our data has demonstrated that
DuP-697 induced apoptosis in HUVECs may be caspase-
dependent while the inhibition of tubule formation may occur
through a caspase-independent mechanism.
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